Head-To-Head Contrast: CERo Therapeutics (NASDAQ:CERO) vs. CASI Pharmaceuticals (NASDAQ:CASI)

CASI Pharmaceuticals (NASDAQ:CASI) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk.

Volatility & Risk

CASI Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500.

Profitability

This table compares CASI Pharmaceuticals and CERo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
CERo Therapeutics	N/A	N/A	-209.40%

Analyst Recommendations

This is a summary of recent recommendations and price targets for CASI Pharmaceuticals and CERo Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1	0	1	0	2.00
CERo Therapeutics	1	2	0	0	1.67

CASI Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 1,827.71%. CERo Therapeutics has a consensus target price of $45.00, suggesting a potential upside of 166,566.67%. Given CERo Therapeutics’ higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than CASI Pharmaceuticals.

Earnings & Valuation

This table compares CASI Pharmaceuticals and CERo Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85 million	0.10	-$39.26 million	($3.01)	-0.07
CERo Therapeutics	N/A	N/A	-$8.30 million	($102.61)	0.00

CERo Therapeutics has lower revenue, but higher earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of CERo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

CASI Pharmaceuticals beats CERo Therapeutics on 7 of the 12 factors compared between the two stocks.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.